Respiratory syncytial virus (RSV) was associated with 190,000 to 350,000 hospitalizations from July 1, 2024, to June 30, 2025, as well as 10,000 to 23,000 deaths, according to data published last month by the Centers for Disease Control and Prevention (CDC).
During the same time, COVID-19 was associated with an estimated 290,000 to 450,000 hospitalizations and 34,000 to 53,000 deaths.
COVID-19 continues to peak twice a year, according to the CDC. About 18% of COVID-19 cases during this period were reported in August, with a smaller surge in early January, when nearly 7% of cases were reported.
The highest COVID-19 hospitalization rates were in people age 75 and older, with 933 hospitalizations per 100,000 people; infants under six months, with 286 hospitalizations per 100,000 people; and adults age 65 to 74, with 274 hospitalizations per 100,000 people.
All SARS-CoV-2 viruses sequenced during this time are descendants of the JN.1 variant, making last year the first season without a new dominant strain replacement since the beginning of the COVID-19 pandemic.
The data were published February 19 in the CDC’s flagship publication, Morbidity and Mortality Weekly Report.
RSV poses the greatest threats to the youngest and oldest people
Although most people with RSV develop symptoms similar to a cold, some can become very sick and die from the virus, which tends to spread in fall and winter.
RSV-associated hospitalization rates were highest among babies under 1 year old, at a rate of 1,117 cases per 100,000 people, followed by children age 12 to 23 months (770 cases per 100,000 people) and adults age 75 or older (427 cases per 100,000).
During this time period, the percentage of positive RSV tests peaked at 11% during the week ending December 21, 2024. RSV was reported at epidemic levels from November 9, 2024, to March 29, 2025.
.jpg)